Cost-effectiveness of ranibizumab in the treatment of visual impairment due to diabetic macular edema

Journal of Medical Economics

Volumn 19, Issue 7, 2016, Pages 663-671

  Haig, Jennifer ^a   Barbeau, Martin ^b   Ferreira, Alberto ^c  

^a OPTUM   (United States)

^b Novartis Pharma Canada Inc   (Canada)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cost effectiveness analysis; Diabetic retinopathy; Markov process; Ranibizumab

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIABETIC MACULAR EDEMA; DRUG WITHDRAWAL; HEALTH CARE SYSTEM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LASER COAGULATION; MAJOR CLINICAL STUDY; MIDDLE AGED; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; QUEBEC; VISUAL IMPAIRMENT; AGED; CANADA; COST BENEFIT ANALYSIS; COST OF ILLNESS; DIABETES COMPLICATIONS; ECONOMICS; FEMALE; HEALTH SERVICE; MACULAR EDEMA; MALE; MARKOV CHAIN; MULTIMODALITY CANCER THERAPY; PROCEDURES; UTILIZATION; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; CANADA; COMBINED MODALITY THERAPY; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DIABETES COMPLICATIONS; FEMALE; HEALTH SERVICES; HUMANS; LASER COAGULATION; MACULAR EDEMA; MALE; MARKOV CHAINS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; QUEBEC; RANIBIZUMAB; VISUAL ACUITY;

EID: 84961215886     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2016.1154566     Document Type: Article

References (57)

1. J.W.Yau, S.L.Rogers, R.Kawasaki,. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556–64
2. P.Mitchell, F.Bandello, U.Schmidt-Erfurth,. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615–25
3. U.Schmidt-Erfurth, G.E.Lang, F.G.Holz,. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology 2014;121:1045–53
4. M.J.Elman, L.P.Aiello, R.W.Beck,. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064–77
5. M.J.Elman, N.M.Bressler, H.Qin,. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011;118:609–14
6. P.Massin, F.Bandello, J.G.Garweg,. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010;33:2399–405
7. Q.D.Nguyen, D.M.Brown, D.M.Marcus,. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119:789–801
8. Q.D.Nguyen, S.M.Shah, J.S.Heier,. Primary end point (Six Months) results of the ranibizumab for edema of the mAcula in Diabetes (READ-2) study. Ophthalmology 2009;116:2175–81
9. Q.D.Nguyen, S.M.Shah, A.A.Khwaja,. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2010;117:2146–51
10. M.Ohji, T.Ishibashi, Sr., and REVEAL study group. Efficacy and safety of ranibizumab 0.5 mg as monotherapy or adjunctive to laser versus laser monotherapy in Asian patients with visual impairment due to diabetic macular edema: 12-month results of the REVEAL Study. Invest Ophthalmol Vis Sci 2012;53:ARVO E-abstract 4664
11. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. 3rd edn, Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006. https://www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdf. Accessed January 4, 2016
12. S.A.Regnier, W.Malcolm, J.Haig, et al. Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective. Clinicoecon Outcomes Res 2015;7:235–47
13. P.Mitchell, L.Annemans, M.Gallagher,. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. Br J Ophthalmol 2012;96:688–93
14. Statistics Canada. Table 102-0504 - Deaths and mortality rates, by age group and sex, Canada, provinces and territories, annual, CANSIM (database). Canada: Statistics Canada; 2008–2012. http://cansim2.statcan.gc.ca/cgi-win/cnsmcgi.exe?Lang=E&CNSM-Fi=CII/CII_1-eng.htm. Accessed June 22 2013
15. Public Health Agency of Canada. Diabetes data. http://www.phac-aspc.gc.ca/ccdpccpcmc/ndss-snsd/english/diabetes_data/index-eng.php. Accessed December 1, 2011. (Link no longer accessible - data on file)
16. F.E.Hirai, M.D.Knudtson, B.E.Klein,. Clinically significant macular edema and survival in type 1 and type 2 diabetes. Am J Ophthalmol 2008;145:700–6
17. Avis au Ministre de L’institut National D’excellence En Santé Et En Services Sociaux. OZURDEXMC – Œdème maculaire consécutif à l’occlusion de la veine centrale de la rétine. 2012 https://www.inesss.qc.ca/fileadmin/doc/INESSS/Inscription_medicaments/Avis_au_ministre/Fevrier_2012/_Avis_ministre_innovateurs201202.pdf. Accessed January 19, 2016
18. C.Czoski-Murray, J.Carlton, J.Brazier,. Valuing condition-specific health states using simulation contact lenses. Value Health 2009;12:793–9
19. R.F.Balshaw, J.Gonder, A.Ferreira,. Evaluation of health utility in patients with retinal vein occlusion. Value Health 2012;15:A572
20. Diabetic Retinopathy Clinical Research Network, R.W.Beck, A.R.Edwards,. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127:245–51
21. A.Cruess, G.Zlateva, X.Xu,. Burden of illness of neovascular age-related macular degeneration in Canada. Can J Ophthalmol 2007;42:836–43
22. Access Economics Pty Limited. Access Economics Pty for the CNIB and the Canadian Ophthalmological Society 'The cost of vision loss in Canada. 2009. http://www.cnib.ca/eng/cnib%20document%20library/research/covl_full_report.pdf'. Accessed January 19, 2015
23. M.M.Brown, G.C.Brown, J.D.Stein,. Age-related macular degeneration: economic burden and value-based medicine analysis. Can J Ophthalmol 2005;40:277–87
24. S.L.Chou, R.Misajon, J.Gallo,. Measurement of indirect costs for people with vision impairment. Clin Experiment Ophthalmol 2003;31:336–40
25. A.F.Cruess, G.Zlateva, X.Xu,. Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study. Pharmacoeconomics 2008;26:57–73
26. S.Cugati, J.J.Wang, E.Rochtchina,. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol 2006;124:726–32
27. K.D.Frick, E.V.Basilion, C.L.Hanson,. Estimating the burden and economic impact of trachomatous visual loss. Ophthalmic Epidemiol 2003;10:121–32
28. K.D.Frick, E.W.Gower, J.H.Kempen,. Economic impact of visual impairment and blindness in the United States. Arch Ophthalmol 2007;125:544–50
29. O.P.Gupta, G.C.Brown, M.M.Brown Age-related macular degeneration: the costs to society and the patient. Curr Opin Ophthalmol 2007;18:201–5
30. J.E.Keeffe, S.L.Chou, E.L.Lamoureux The cost of care for people with impaired vision in Australia. Arch Ophthalmol 2009;127:1377–81
31. R.Klein, B.E.Klein, S.C.Jensen,. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1997;104:7–21
32. A.Lafuma, A.Brezin, F.Fagnani,. Nonmedical economic consequences attributable to visual impairment: a nation-wide approach in France. Eur J Health Econ 2006;7:158–64
33. E.L.Lamoureux, S.L.Chou, M.F.Larizza,. The reliability of data collection periods of personal costs associated with vision impairment. Ophthalmic Epidemiol 2006;13:121–6
34. A.Lotery, X.Xu, G.Zlatava,. Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: results from the UK cohort of a five-country cross-sectional study. Br J Ophthalmol 2007;91:1303–7
35. M.E.McClure, P.M.Hart, A.J.Jackson,. Macular degeneration: do conventional measurements of impaired visual function equate with visual disability? Br J Ophthalmol 2000;84:244–50
36. C.B.Roberts, Y.Hiratsuka, M.Yamada,. Economic cost of visual impairment in Japan. Arch Ophthalmol 2010;128:766–71
37. J.M.Ruiz-Moreno, R.M.Coco, J.Garcia-Arumi,. Burden of illness of bilateral neovascular age-related macular degeneration in Spain. Curr Med Res Opin 2008;24:2103–11
38. J.K.Schmier, M.T.Halpern, D.Covert,. Impact of visual impairment on use of caregiving by individuals with age-related macular degeneration. Retina 2006;26:1056–62
39. A.F.Smith The economic impact of ophthalmic services for persons with diabetes in the Canadian Province of Nova Scotia: 1993-1996. Ophthalmic Epidemiol 2001;8:13–25
40. T.S.Smith, K.D.Frick, B.A.Holden,. Potential lost productivity resulting from the global burden of uncorrected refractive error. Bull World Health Organ 2009;87:431–7
41. H.R.Taylor, M.L.Pezzullo, J.E.Keeffe The economic impact and cost of visual impairment in Australia. Br J Ophthalmol 2006;90:272–5
42. J.Thygesen, M.Aagren, S.Arnavielle,. Late-stage, primary open-angle glaucoma in Europe: social and health care maintenance costs and quality of life of patients from 4 countries. Curr Med Res Opin 2008;24:1763–70
43. E.Y.Wong, S.L.Chou, E.L.Lamoureux,. Personal costs of visual impairment by different eye diseases and severity of visual loss. Ophthalmic Epidemiol 2008;15:339–44
44. J.K.Schmier, M.T.Halpern, D.W.Covert,. Impact of visual impairment on service and device use by individuals with age-related macular degeneration (AMD). Disabil Rehabil 2006;28:1331–7
45. F.Ismail-Beigi, T.Craven, M.A.Banerji,. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010;376:419–30
46. S.E.Moss, R.Klein, B.E.Klein The incidence of vision loss in a diabetic population. Ophthalmology 1988;95:1340–8
47. S.E.Moss, R.Klein, B.E.Klein Ten-year incidence of visual loss in a diabetic population. Ophthalmology 1994;101:1061–70
48. V.Dewan, D.Lambert, J.Edler,. Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2012;119:1679–84
49. J.D.Stein, P.A.Newman-Casey, D.D.Kim,. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema. Ophthalmology 2013;120:1835–42
50. A.G.Malkin, J.E.Goldstein, M.S.Perlmutter,. Responsiveness of the EQ-5D to the effects of low vision rehabilitation. Optom Vis Sci 2013;90:799–805
51. S.Kay, A.Ferreira Mapping the 25-item National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) to EQ-5D utility scores. Ophthalmic Epidemiol 2014;21:66–78
52. Diabetic Retinopathy Clinical Research Network, J.A.Wells, A.R.Glassman,. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015;372:1193–203
53. Régie de l'assurance maladie du Québec. Liste de médicaments. 2013. http://www.ramq.gouv.qc.ca/en/regie/legal-publications/Pages/list-medications.aspx. Accessed January 19, 2015
54. Régie de l'assurance maladie du Québec. Manuel des médecins spécialistes, MAJ 84. http://collections.banq.qc.ca/ark:/52327/bs2272062. Accessed January 19, 2015
55. M.M.Brown, G.C.Brown, S.Sharma,. Utility values and diabetic retinopathy. Am J Ophthalmol 1999;128:324–30
56. S.Sharma, G.C.Brown, M.M.Brown,. Converting visual acuity to utilities. Can J Ophthalmol 2000;35:267–72
57. J.Lachaine, C.Beauchemin, K.Mathurin Productivity losses related to vision impairment. A literature review and estimation of costs to include in the Lucentis® pharmacoeconomic model. 2011